Biopharmaceutical - Edgentiq

Absci Shifts Focus to AI-Driven ABS-201 Program, Reports Q3 2025 Financials

Harbour BioMed Unveils Groundbreaking Generative AI Model for Accelerated Biologics Discovery

Almirall and Absci Broaden AI-Powered Dermatological Drug Discovery Alliance

AbbVie Bolsters Cybersecurity with AI/ML Expertise in Threat Intelligence

AI Ethics and Privacy Take Center Stage in Biopharmaceutical Industry Discussions

spot_img

Recently Added

Absci Navigates Q2 2025 Revenue Dip with Strategic Capital Infusion and AI-Driven Pipeline Advancements

Read more

Almirall and Absci Broaden AI-Powered Drug Discovery Partnership with New Dermatology Target

Read more

Lianhe Sowell International Group Secures Significant Investment for Robotics Innovation and Manufacturing Expansion

Read more

Gen AI News and Updates

spot_img

- Advertisement -

Absci Shifts Focus to AI-Driven ABS-201 Program, Reports Q3 2025 Financials

November 13, 2025

Harbour BioMed Unveils Groundbreaking Generative AI Model for Accelerated Biologics Discovery

October 29, 2025

Almirall and Absci Broaden AI-Powered Dermatological Drug Discovery Alliance

August 27, 2025